单位：1.中山大学附属第一医院 胃肠外科中心， 广东 广州 510080; 2.中山大学附属第七医院 消化医学中心, 广东 深圳 517108

Authors: Zhang Jie1，Cai Qinbo1，Chen Huanjie1，Fu Huafeng1，Hou Haobin1，Huang Jiahua1，He Yulong2

Unit: 1.Gastrointestinal Surgery Center, the First Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China; 2.Gastroenterology Center, the Seventh Hospital of Sun Yat-sen University, Shenzhen 510080, Guangdong, China

摘要：

目的 分析SLC25A13的表达与胃癌临床病理特点及预后的相关性。方法 本研究回顾性选取了从2010年1月至2014年12月在中山大学附属第一医院胃肠外科中心接受根治性切除的确诊胃癌Ⅰ～Ⅲ期的患者。通过免疫组织化学染色评分将患者从蛋白水平上分为SLC25A13低表达组和高表达组；进一步分析了SLC25A13表达水平与胃癌的临床病理特点，5年总生存率和5年无复发生存率之间的关系。并采用单因素和多因素Cox比例风险模型分析探讨SLC25A13高表达是否为胃癌患者预后的独立危险因素。结果 根据SLC25A13表达水平将195例胃癌患者划分为60例SLC25A13低表达患者与134例SLC25A13高表达的患者，两组患者在肿瘤直径、分化程度、T和N分期及总TNM分期等方面的差异均有统计学意义（P<0.05），在性别、年龄、肿瘤分化程度上差异均无统计学意义。Kaplan-Meier生存分析显示SLC25A13高表达组5年生存率为32.1%，生存时间为36个月，5年无复发生存率为68.2%，无复发时间为48个月。单因素Cox比例风险模型分析提示分化程度，T分期，N分期和SLC25A13高表达是5年总生存时间的危险因素，其中T分期(HR=2.697, 95%CI:1.134～6.415, P=0.025)、N分期(HR=3.051, 95%CI:1.937～4.805, P<0.001)是独立危险因素；N分期和SLC25A13高表达是5年无复发生存时间的危险因素，其中T分期(HR=3.658, 95%CI:1.043～12.823,P=0.018)是独立危险因素。结论 SLC25A13高表达与胃癌肿瘤直径大、分化差、分期晚以及较差的预后相关，提示SLC25A13高表达是胃癌的危险因素。 

关键词：SLC25A13； 临床病理特征； 生存分析； 预后因素

Abstract：

Objective Analyze the clinicopathological features，overall survival rate and prognostic significance of gastric cancer with high and low expression of SLC25A13. Method This study retrospectively selected consecutive patients with stage I to Ⅲ gastric adenocarcinoma who underwent radical resection in the Gastrointestinal Surgery Center of the First Affiliated Hospital of Sun Yat -sen University from January 2010 to December 2014.The patients were divided into SLC25A13 low expression group and high expression group by immunohistochemical staining score. The relationship between the expression level of SLC25A13 and the clinicopathological features，5-year overall survival rate and 5-year recurrence-free survival rate of gastric cancer was further analyzed. Univariate and multivariate Cox proportional risk models were used to investigate whether high expression of SLC25A13 was an independent prognostic risk factor for patients with gastric cancer. Result In this study，195 patients with gastric cancer were divided into 60 patients with low expression of SLC25A13 and 135 patients with high expression of SLC25A13 at the protein level. The tumor diameter，degree of differentiation，There were statistically significant differences in T and N stages and total TNM stages（P<0.05 ） ， but there were no statistically significant differences in gender ，age and degree of tumor differentiation. Kaplan-Meier survival analysis showed that the 5-year survival rate of SLC25A13 high expression group was 32.1%，the survival time was 36 months，the 5-year recurrence-free survival rate was 68.2%，and the recurrence-free time was 48 months; Univariate Cox proportional hazards model analysis indicated that degree of differentiation，T stage，N stage and high expression of SLC25A13 were risk factors for 5-year overall survival，among which T stage (HR=2.697，95%CI:1.134~6.415，P=0.025)，N stage (HR=3.051, 95%CI:1.937~4.805，P<0.001) is independent risk factor. T stage，N stage and high expression of SLC25A13 were risk factors for five-year recurrence-free survival time，among which T stage(HR=3.658，95%CI:1.043~12.823，P=0.018) was independent risk factor. Conclusion High expression of SLC25A13 is associated with large tumor diameter，poor differentiation，late stage and poor prognosis of gastric cancer，suggesting that high expression of SLC25A13 is a risk factor for gastric cancer.

Key Words: SLC25A13； Clinicopathological characteristics； Survival analysis； Prognostic factor